Work

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Year: 2025

Type: article

Abstract: Cladribine tablets (CladT) represent an effective immune reconstitution therapy, administered in short treatment courses over two consecutive years. To better understand the amplitude of immune changes, we performed a comprehensive analysis during the 2-year study period for the entire MAGNIFY-MS population (N=270). In addition to lymphocyte kinetics, we studied intracellular cytokines serum proteins, and their associations with clinical outcomes. To put these changes into perspective, we analyzed transcriptional changes in T and B cells and associated biological pathways before and after each treatment course with CladT.

Source: Open Access CRIS of the University of Bern

DOI: 10.48620/85127

Authors: Wiendl, Heinz, Barkhof, Frederik, Montalban, Xavier, Achiron, Anat, Derfuss, Tobias, Chan, Andrew, Hodgkinson, Suzanne, Prat, Alexandre, Leocani, Letizia, Schmierer, Klaus, Sellebjerg, Finn, Vermersch, Patrick, Jin, Hulin, Chudecka-głaz Anita, Kloetgen, Andreas, Dongdong, Lin, Gardner, Lidia, De Nicola Stefano

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6966608941

FWCI:

Cites:

Cited by:

Related to: